HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,857-2,868 of 4,505
Drug study icon
TerminatedNCT01712646

Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia

Official study title

The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial

This study ended early.

In Bethesda
SchizophreniaMedication studyAges 10–99
Countries
United States
Sponsor
National Institute of Mental Health (NIMH) (Government agency)
Other study type icon
CompletedNCT02187835

Decreased EEG Complexity in Schizophrenia

Official study title

Decreased EEG Complexity in Chronic Residual Schizophrenia

This study has finished and is no longer accepting participants.

In Istanbul
SchizophreniaObservational studyAges 18–65
Countries
Türkiye
Sponsor
Uskudar University
Other study type icon
CompletedNCT01689389

Quetiapine Extended-Release Use in Routine Care in France

About this title

Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study

Read the official source — NCT01689389
Official study title

Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France

This study has finished and is no longer accepting participants.

Multiple locations, including Argenteuil
Schizophrenia, BipolarityObservational studyAges 18–130
Countries
France
Sponsor
AstraZeneca
Drug study icon
UnknownNCT04892199

Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?

Official study title

Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?

Current recruitment status is unconfirmed.

Multiple locations, including Aarhus
SchizophreniaMedication studyAges 18–65
Countries
Denmark
Sponsor
Anders Fink-Jensen, MD, DMSci
Behavioral study icon
CompletedNCT00783185

Cannabis reduction and social skills training for psychosis

About this title

Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

Read the official source — NCT00783185
Official study title

Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis

This study has finished and is no longer accepting participants.

In Konstanz
SchizophreniaBehavioural studyAges 18–65
Countries
Germany
Sponsor
University of Konstanz
Behavioral study icon
CompletedNCT00204061

Amisulpride with supportive care for late early-warning signs of psychosis

About this title

Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis

Read the official source — NCT00204061
Official study title

Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis

This study has finished and is no longer accepting participants.

In Cologne
SchizophreniaMedication studyAges 14–36
Countries
Germany
Sponsor
University of Cologne

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.